Expertise in
3
conditions

Dr. Brian Weiss

Intensive Care Medicine
Office
111 S 11th St Ste 8490, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Referral may be required
Expertise in
3
conditions
Office
111 S 11th St Ste 8490, 
Philadelphia, PA 

Overview

Brian Weiss is an Intensive Care Medicine provider practicing medicine in Philadelphia, Pennsylvania.

Dr. Weiss is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Ganglioneuroblastoma, Aplasia Cutis Congenita, Lithotripsy, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 21 clinical trials.

Specialties

Intensive Care Medicine

Licenses

Emergency Medicine in OH

Hospital Affiliations

Thomas Jefferson University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

Office
111 S 11th St Ste 8490, Philadelphia, PA 19107
Other Locations
Select Specialty Hosp-Columbus
410 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 1/Phase 2
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Enrollment Status: Completed
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
Enrollment Status: Terminated
Publish Date: March 10, 2026
Intervention Type: Other, Procedure, Behavioral, Drug, Genetic
Study Drugs: Ribociclib, Ceritinib
Study Phase: Phase 1
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drug: Lutathera
Study Phase: Phase 2
View 9 Less Clinical Trials

67 Total Publications

Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.
Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Similar Doctors
Expertise in
33
conditions
Dr. Gerard Criner
Intensive Care Medicine
Expertise in
33
conditions
Dr. Gerard Criner
Intensive Care Medicine

Temple University Hospital

3401 N Broad St, 
Philadelphia, PA 
 (3.9 miles away)
215-707-1722
Languages Spoken:
English
See accepted insurances

Gerard Criner is an Intensive Care Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Criner is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Bronchitis, Lung Transplant, and Embolectomy.

Expertise in
12
conditions
Dr. Joshua Diamond
Intensive Care Medicine
Expertise in
12
conditions
Dr. Joshua Diamond
Intensive Care Medicine

Penn Renal Electrolyte And Hypertension Perelman

3400 Civic Center Blvd Fl 1, 
Philadelphia, PA 
 (2.2 miles away)
215-662-3202
Languages Spoken:
English
See accepted insurances

Joshua Diamond is an Intensive Care Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Diamond is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Bronchiolitis Obliterans, Lung Transplant, and Thalamotomy.

Expertise in
16
conditions
Dr. Parth Rali
Intensive Care Medicine
Expertise in
16
conditions
Dr. Parth Rali
Intensive Care Medicine

Temple University Hospital

3401 N Broad St, 
Philadelphia, PA 
 (3.9 miles away)
215-707-5864
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Parth Rali is an Intensive Care Medicine provider practicing medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 17 years. Dr. Rali is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Lung Metastases, Embolectomy, and Thrombectomy.

Frequently Asked Questions about Dr. Brian Weiss

How do I make an appointment with Dr. Brian Weiss?

You can book an appointment with Dr. Brian Weiss by calling their office at 215-955-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian Weiss a top-rated expert for Neurofibromatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian Weiss is classified as an Elite expert for Neurofibromatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian Weiss specialize in?

While Dr. Brian Weiss is a Intensive Care Medicine, they have specific expertise in Neurofibromatosis, Ganglioneuroblastoma, and Lithotripsy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Brian Weiss participate in research or clinical trials?

Yes. Dr. Brian Weiss has published 67 articles and abstracts on conditions like Neurofibromatosis. You can view a list of Dr. Brian Weiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian Weiss accept my insurance?

Dr. Brian Weiss accepts most major insurance plans, including CareSource and Independent Health. We recommend calling the office directly at 215-955-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile